THE NEW ARMENIAN MEDICAL JOURNAL
Volume18 (2024), Issue 3 p.60-68

DOI: https://doi.org/10.56936/18290825-3.v18.2024-60

NONINVASIVE PROTEOMIC BIOMARKER IN DISORDERS OF THE NONALCOHOLIC FATTY LIVER

Bari Md N.[1]*, Osman E.H.A.[2], Alfaki M.A.[1], Ansari Md R.[1]

[1]. Department of Basic Medical Sciences, College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.

[2]. College of Nursing and Health Sciences Department of Diagnostic Radiology in Jazan University Saudi Arabia.

Received 21.02.2023 Accepted for printing 04.08.2024

Abstract

Fatty liver disease that is not alcoholic, often known as non-alcoholic fatty liver disease, is a common and progressive liver ailment that is defined by an abnormal buildup of fat in the liver when significant alcohol use is avoided.

Nonalcoholic fatty liver disease is a frequent and progressive liver disorder. A variety of conditions are referred to as nonalcoholic fatty liver disease, which might include nonalcoholic steatohepatitis and simple steatosis. which can eventually lead to cirrhosis and hepatocellular cancer. Among nonalcoholic fatty liver disease, simple steatosis is the most prevalent kind. Even though it is invasive and has various drawbacks, liver biopsy is still considered the gold standard for diagnosing and staging nonalcoholic fatty liver disease at the present time. As a result, there is an immediate need for noninvasive biomarkers that are capable of providing an accurate diagnosis, staging, and monitoring of the development of illness.

In recent years, proteomic methods have emerged as potentially useful tools for the identification and validation of noninvasive biomarkers in nonalcoholic fatty liver disease. This development has place over the course of many years.

The objective of this research study is to provide an overview of the existing situation of noninvasive proteomic biomarkers in nonalcoholic fatty liver disease as well as their possible implications in clinical practice.

Keywords: *nonalcoholic fatty liver disease (NAFLD), proteomic biomarkers, noninvasive diagnosis, liver disease, metabolic syndrome, biomarker discovery, mass spectrometry, proteomics, liver biopsy, disease progression.*

Introduction

The condition known as nonalcoholic fatty liver disease (NAFLD) has become a significant public health concern issue, since it affects a sizeable percentage of people all over the globe. It is distinguished by the buildup of fat in the liver of people who don't drink a considerable quantity of alcohol, which is the defining characteristic of the condition. A range of liver illnesses are referred to as NAFLD that range from simple steatosis (fatty liver) to non-alcoholic steatohepatitis (NASH), which is characterized by inflammation and damage to the hepatocellular tissue of the liver. An elevated risk of severe fibrosis, cirrhosis, and perhaps hepatocellular carcinoma (HCC) exists in patients with NASH [*Ahn S et al., 2010*].

The growing worldwide epidemics of obesity, insulin resistance, and metabolic syndrome are directly connected to the incidence of fatty liver dis-

Cite This Article as:

Bari Md N., Osman E.H.A., Alfaki M.A. , Ansari Md R. (2024). Noninvasive proteomic biomarker in disorders of the nonalcoholic fatty liver: A systematic review, The New Armenian Medical Journal, vol.18(2), 60-67; https://doi.org/ 10.56936/18290825-3.v18.2024-60

Address for Correspondence:

Nadeem Bari, MD
Department of Basic Medical Sciences College of Medicine, Prince Sattam bin Abdulaziz University
Al-Kharj 11942, Saudi Arabia
Tel.: +966509280389
E-mail: nadeembari273@gmail.com

ease not caused by alcohol (NAFLD) [*Anstee Q et al., 2013*]. The prevalence of NAFLD is believed to be somewhere around 25 percent of people on the planet, and it is anticipated that its prevalence will grow in tandem with the obesity pandemic. The nonalcoholic fatty liver disease is not only a huge burden on public health, but it also leads to increased morbidity and death owing to problems associated to the liver [*Bessone F et al., 2019*].

NAFLD and its Clinical Spectrum: The risk of developing NAFLD is increased by a number of variables, including genetics, the environment, and lifestyle choices. the development of fatty liver disease without alcohol is caused by a complicated interaction between metabolic dysfunction, oxidative stress, inflammation, and anomalies in hepatic lipid metabolism. The clinical spectrum of NAFLD includes a wide variety of diseases, beginning with simple steatosis, which is characterized by the accumulation of fat in hepatocytes but does not cause severe liver impairment. Even while simple steatosis is often seen as a harmless illness, it may develop into more severe stages over time [*Buzzetti E et al., 2016*]. The term non-alcoholic steatohepatitis refers to a more severe form of non-alcoholic fatty liver disease, which is characterized by hepatic inflammation, hepatocellular damage, and various degrees of fibrosis. A higher likelihood of developing progressive liver disease, such as cirrhosis and HCC, is linked to having NASH. The correct diagnosis and staging of NAFLD are very necessary in order to choose the most effective treatment options, evaluate the course of the illness, and forecast the results for individual patients [*Chalasani N et al., 2018*].

Challenges in Current Diagnostic Approaches: At the moment, a liver biopsy is regarded as the diagnostic and staging method of choice for NAFLD that should be followed. The liver biopsy, on the other hand, is an intrusive operation that comes with the risk of possible consequences, variable sampling, and patient resistance. Because liver biopsies are invasive, expensive, and need the interpretation of a specialist, it is impracticable to do them on a wide scale in a clinical setting [*Charlton M et al., 2009*].

As a result, there is a pressing need for diagnostic techniques that do not need invasive procedures and are capable of reliably identifying NAFLD as well as its stage. Biomarkers that are not invasive have the potential to lessen the need for liver biopsies, make early identification possible, improve risk classification, and direct individualized treatment choices [*Cui J et al., 2015*]. In addition, the availability of noninvasive biomarkers would make it possible to perform regular monitoring of the development of illness and the patient's response to treatment measures.

In recent years, proteomic techniques have received attention as prospective tools for the development and validation of noninvasive biomarkers in NAFLD. This focus has been acquired as a result of the fact that proteome approaches are relatively new. Proteomics allows for the discovery of disease-associated protein signatures by providing a complete examination of the whole protein complement expressed in a tissue or biological sample.

In this study work, one of our primary goals is to offer an overview of the present status of noninvasive proteomic biomarkers in NAFLD [*DiStefano J et al., 2018*]. We will investigate the various proteomic technologies that are used for the discovery of biomarkers, discuss the proteomic biomarkers that have been identified for diagnosis, staging, and prognosis, and then discuss the difficulties that have been encountered as well as the opportunities that lie ahead in terms of implementing these biomarkers in clinical practice. The discovery of proteomic biomarkers that do not need invasive procedures has the potential to completely transform the diagnosis, monitoring, and treatment of NAFLD. As a result, patient outcomes will likely improve, and the burden placed on healthcare systems will be reduced [*Doulberis M et al., 2017*].

Proteomic technologies for NAFLD biomarker discovery

The use of proteomic technology has become more important in the process of identifying biomarkers associated with NAFLD. These methods make it possible to conduct an in-depth investigation of the proteome, which is comprised of all the proteins that are expressed in a particular tissue or biological sample. Proteomics provides insights into the disease processes as well as the discovery of possible biomarkers, and it does this by investigating the protein patterns and modifications that occur in NAFLD [*Eslam M, 2020*].

Mass Spectrometry-Based Proteomics: The method known as mass spectrometry is essential to the field of proteomics since it permits the identification and quantification of proteins on the basis of the ratio of their mass to their charge. The proteome may be analyzed in either a targeted or unbiased manner by using mass spectrometry-based proteomics.

Research on nonalcoholic fatty liver disease has made extensive use of mass spectrometry-based proteomics to discover proteins with variable expression, post-translational changes, and protein-protein interactions. Analyzing the complex protein mixtures found in liver tissue, blood, urine, and other biological fluids has been accomplished through the use of methodologies such as matrix-assisted laser desorption/ionization mass spectrometry and liquid chromatography combined with tandem mass spectrometry (liquid chromatography-mass spectrometry/mass spectrometry). These methodologies make it possible to identify and quantify particular protein biomarkers that are linked with the aetiology of NAFLD, as well as the course of the illness and the patient's response to therapy [*Geyer P, 2017*].

Protein Microarrays: Protein microarrays are high-throughput systems that make it possible to conduct the simultaneous study of hundreds of different proteins in a single experiment. On a solid surface, they are made up of immobilized capture molecules such as antibodies or recombinant proteins [*Li Z et al., 2020*].

Research on nonalcoholic fatty liver disease has made use of protein microarrays for the identification and measurement of protein biomarkers in patient samples. These arrays make it possible to screen a vast number of proteins, such as cytokines, growth factors, enzymes, and signaling molecules, in order to uncover unique signatures that are linked to the development, progression, and severity of NAFLD. Protein microarrays have a number of advantages, including high sensitivity, the capacity to multiplex, and the possibility of customized treatment as a result of the discovery of unique protein profiles [*Li Z, et al., 2020*].

Other Proteomic Approaches:Other proteomic methods, in addition to mass spectrometry and protein microarrays, have made important contributions to the finding of NAFLD biomarkers.

Two-dimensional gel electrophoresis, often known as 2D-GE, is a tried-and-true method for separating proteins according to their respective molecular weights and isoelectric points. In the study of NAFLD, this strategy has been used to the task of identifying proteins whose expression levels vary between the control group and the NAFLD samples. Nevertheless, 2D-GE has limitations when it comes to identifying proteins with a low abundance and post-translational modifications [*Li Z, et al., 2020*].

Shotgun proteomics, also known as bottom-up proteomics, begins with the digestion of proteins into peptides, which is then followed by the separation of the peptides using mass spectrometry and the determination of their identities. This method enables high-throughput screening of complicated protein mixtures and has been used in the process of identifying protein biomarkers related with the development and progression of NAFLD.

In addition, novel proteomic technologies, such as data-independent acquisition and label-free quantification approaches, are finding an increasing amount of use in the research and development of NAFLD biomarkers. These methods improve the accuracy and repeatability of protein measurement while also providing a more complete coverage of the proteome.

In general, proteomic technologies provide strong tools that may be used for the finding of biomarkers in NAFLD. These approaches contribute to a deeper understanding of NAFLD pathogenesis and facilitate the development of noninvasive biomarkers for diagnosis, staging, prognosis, and therapeutic monitoring. They do this by enabling the analysis of the entire proteome and the identification of disease-associated protein alterations [*Liu Y et al., 2019*].

Proteomic biomarkers in NAFLD

Nonalcoholic fatty liver disease (NAFLD) is a complex and heterogeneous condition that encompasses a spectrum of liver disorders. These disorders range from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Nonalcoholic fatty liver disease (NAFLD) is abbreviated as NAFLD. The proper treatment and prognosis cannot be determined without first obtaining an accurate diagnosis and

staging of NAFLD. Traditional diagnostic procedures, such as a liver biopsy, are regarded the gold standard; nevertheless, these diagnostic procedures are intrusive, costly, and pose some risk. As a result, the discovery of biomarkers that do not need invasive procedures is of significant interest in NAFLD research [*Machado M et al., 2015*].

Technologies based on proteomics have recently emerged as useful methods for the finding of biomarkers in NAFLD. Proteomics is the study of the whole complement of proteins that are expressed in a particular tissue or biological sample. This research may provide useful insights into the underlying causes of illness as well as the discovery of possible biomarkers. Research on NAFLD has made use of a number of different proteomic technologies, including as mass spectrometry-based proteomics, protein microarrays, and other high-throughput methods [*Mantovani A, 2018*].

Biomarkers for Diagnosis and Disease Staging: Research on NAFLD has a number of goals, one of the most important of which is to find non-invasive biomarkers that would allow for precise diagnosis and staging of the illness. Several proteomic investigations have been conducted, and the results of these research have led to the identification of possible protein biomarkers that might differentiate healthy persons from those who have NAFLD. Proteins that are involved in lipid metabolism, oxidative stress, inflammation, fibrosis, and cellular damage are included in this group of biomarkers.

For example, the adipocyte-derived protein adiponectin, which possesses insulin-sensitizing and anti-inflammatory characteristics, has been the subject of intense research as a possible diagnostic biomarker in NAFLD. Low levels of adiponectin have been repeatedly linked to both the prevalence and severity of NAFLD. Additional proteins, such as cytokeratins, heat shock proteins, and components of the complement system, have also shown promise as potential diagnostic biomarkers.

Additionally, proteomic studies have identified biomarkers that can differentiate between various stages of NAFLD, such as distinguishing simple steatosis from NASH or identifying advanced fibrosis and cirrhosis. These distinctions are possible thanks to the discovery of biomarkers that can differentiate between these stages. These biomarkers provide very helpful information for determining the prognosis of an illness and directing therapy choices [*Neuman M, 2014*].

Biomarkers for Distinguishing NASH from Simple Steatosis:It is very essential to differentiate between basic steatosis and NASH, since NASH has a greater risk of disease development and consequences than simple steatosis does. Research using proteomics has led to the discovery of possible biomarkers that may differentiate between these two disorders. Proteins that are involved in lipid metabolism, oxidative stress, inflammation, and fibrosis are some examples of these indicators.

For instance, multiple studies have revealed a difference in the expression of proteins that are involved in the pathways of hepatic lipid metabolism in NASH when compared to simple steatosis. These proteins include fatty acid-binding proteins and Acyl-CoA binding proteins, among others. In addition, proteins that are involved with oxidative stress, such as glutathione peroxidases and superoxide dismutases, have demonstrated expression patterns that are distinct from one another in both NASH and simple steatosis [*Povero D et al., 2015*].

Biomarkers for Disease Progression and Prognosis:It is essential for the optimal management and tailored therapy of NAFLD patients to have an accurate forecast of the course of the illness and the prognosis. Studies on proteomics have led to the discovery of possible biomarkers that might signal the course of a disease, the risk of developing advanced fibrosis or cirrhosis, and the possibility of developing hepatocellular carcinoma (HCC).

There is evidence that markers of fibrosis, including matrix metalloproteinases, tissue inhibitors of metalloproteinases, and collagens, are associated with the course of illness. In individuals who have NAFLD, an altered expression of proteins that are involved in cell cycle control, apoptosis, and cellular stress responses has been linked to an increased risk of developing hepatocellular carcinoma (HCC) [*Ratziu V et al., 2005*].

Emerging proteomic strategies and technologies

Metabolomics and Lipidomics in NAFLD: Emerging studies within the domain of proteomics, metabolomics and lipidomics are centred on the thorough analysis of small molecules, metabolites,

and lipids in biological samples. Proteomics is the study of proteins and peptides. By investigating the final products and intermediates of cellular metabolism, these methods provide a viewpoint that is complementary to proteomics.

In the setting of NAFLD, metabolomics and lipidomics provide crucial insights into the illness's related altered metabolic pathways and lipid dysregulation. These techniques may discover distinct molecular signatures that correspond with the development, progression, and response to therapy of NAFLD by profiling metabolites and lipids in liver tissue, blood, and other bodily fluids. In nonalcoholic fatty liver disease, metabolomics and lipidomics offer the potential to unearth new biomarkers and therapeutic targets, as well as give a greater knowledge of the metabolic disturbances that are at the root of the illness [*Targher G, 2018*].

Proteogenomics and Integrated Multi-Omics Approaches: The term "proteogenomics" refers to an integrative methodology that integrates data from proteomics with information from genomics and transcriptomics. Proteogenomics is the science that allows for the identification and confirmation of protein-coding genes, alternative splicing processes, and post-translational modifications. It does this by combining data from proteomics and genomics.

In the field of study on NAFLD, proteogenomics offers the ability to decipher the complex relationships that exist between genetic variants, gene expression, and the amount of protein present. Researchers are able to get a more comprehensive knowledge of NAFLD pathogenesis and locate important molecular drivers and pathways if they combine data from many omics. These omics include genomics, transcriptomics, proteomics, metabolomics, and lipidomics [*Wang X et al., 2018*].

Integrated multi-omics techniques make it possible to identify molecular signatures that could not be found using separate omics investigations on their own. Researchers are able to construct full molecular profiles, as well as discover new biomarkers, therapeutic targets, and probable pathways implicated in NAFLD, by merging the data that they get from a variety of omics platforms.

Machine Learning and Artificial Intelligence in Biomarker Discovery: In the realm of biomarker discovery and analysis, machine learning and artificial intelligence approaches have become crucial. These approaches are capable of managing large-scale omics information, identifying relevant patterns, and developing predictive models for illness diagnosis, prognosis, and therapy response.

In the context of NAFLD, machine learning and artificial intelligence algorithms can be applied to proteomic and multi-omics data in order to identify relevant features, classify disease subtypes, predict disease progression, and evaluate treatment outcomes. These methods may improve the accuracy and efficiency of biomarker identification, make customized therapy more feasible, and lend a hand in the process of clinical decision-making.

The creation of risk prediction models and diagnostic algorithms that include clinical, genomic, proteomic, and other relevant data may also benefit from the use of machine learning and artificial intelligence algorithms. These models are able to generate more precise and dependable predictions by combining a variety of information sources, and they may help physicians make educated choices by providing this assistance [*Younossi Z, 2016*].

In conclusion, the application of machine learning and artificial intelligence, along with the development of new proteomic strategies and technologies such as metabolomics, lipidomics, proteogenomics, and integrated multi-omics approaches, are broadening the scope of biomarker discovery in NAFLD and increasing its capabilities. These recent developments offer a great deal of promise for deciphering the complexities of NAFLD and may result in the discovery of new biomarkers, therapeutic targets, and individualized treatment regimens.

Clinical translation and challenges

Clinical Translation of Proteomic Biomarkers: When it comes to the diagnosis, staging, prognosis, and treatment monitoring of nonalcoholic fatty liver disease, one of the most important steps in their implementation is the translation of proteomic biomarkers from research studies to clinical practice. A comprehensive validation and standardization of biomarkers, in addition to resolving a variety of problems and limits, are necessary for the successful translation of research into clinical practice.

In validation studies, the performance properties of biomarkers, such as sensitivity, specificity, accuracy, and predictive value, are evaluated in pa-

tient groups that are vast and varied. The purpose of these research is to demonstrate the clinical usefulness of proteomic biomarkers and evaluate whether or not they have the potential to improve upon previously established diagnostic or prognostic procedures [*Zhou X, Cai D, 2016*].

It is essential to standardize proteomic technologies and procedures in order to ensure repeatability and comparability of findings across a variety of clinical contexts and labs. It is necessary to develop standardized methods for the collecting of samples, the processing of those samples, and the analysis of the data in order to reduce variability and guarantee accurate and consistent biomarker results

In addition, the broad use of biomarker detection methods in clinical labs is contingent on the creation of reliable assays that are intuitively designed for their end users. Validation and optimization of test platforms, such as enzyme-linked immunosorbent assays or targeted mass spectrometry assays, are necessary in order to achieve the desired levels of sensitivity, specificity, and accuracy.

Challenges and Limitations: The clinical translation of proteomic biomarkers in NAFLD is hampered by a number of obstacles and constraints, including the following:

- Nonalcoholic Fatty Liver Disease is a Heterogeneous Disease with Varied Phenotypes and Underlying Molecular Mechanisms. NAFLD is a Heterogeneous Disease. Discovery and validation of biomarkers need to take into consideration the heterogeneity of NAFLD, taking into account the many phases, subtypes, and comorbidities associated with the disease.
- Sample Availability and Accessibility It might be difficult to get patient samples that are typical of the population being studied and that have been well described. It is difficult to get samples of liver tissue by performing a liver biopsy, and noninvasive sampling approaches, such as collecting blood or urine, may not adequately capture the intricacy of liver-specific protein modifications.
- Reproducibility and Standardization: Proteomic technologies are notoriously difficult to replicate and are prone to varying results depending on the laboratory and the platform used. It is essential to standardize the handling of samples, the protocols for conducting experiments, and the techniques for analyzing data in order to guarantee reproducibility and comparability of findings.
- Biomarker Panels and Algorithms Because NAFLD is a complex illness, the diagnostic or prognostic accuracy provided by a single biomarker may not be adequate. It is possible that developing biomarker panels or algorithms that incorporate several protein markers, in addition to clinical and genetic data, may increase the accuracy and prediction ability of the analysis.
- Large-Scale Validation Studies It is very necessary to carry out large-scale validation studies in a variety of patient cohorts in order to determine whether or not proteomic biomarkers have any therapeutic usefulness. In order to evaluate the predictive significance of biomarkers over the long term, these studies need a substantial amount of resources, collaborative efforts, and longitudinal follow-up.
- Cost and Availability: When implementing proteomic biomarkers into clinical practice, it is important to take into account both the cost-effectiveness and the availability of these tools for regular usage. The development of tests that are more time and money efficient, as well as their incorporation into the workflows of clinical laboratories, is required for broad use.
- In spite of these hurdles, current improvements in proteomic technology, multi-omics integration, and data processing approaches provide significant promise for overcoming these constraints and aiding the clinical translation of proteomic biomarkers in non-alcoholic fatty liver disease. The incorporation of proteomic biomarkers into clinical practice has the potential to enhance both the care of NAFLD patients and their results, provided that ongoing research efforts and cooperation between academic institutions, private sector, and regulatory agencies are maintained.

Conclusion

Nonalcoholic fatty liver disease, often known as NAFLD, is a disorder that affects the liver that is both common and progressing, and it presents substantial problems to public health all over the globe. NAFLD has the potential to be a game-changer in terms of disease diagnosis, staging, prognosis, and therapy monitoring, all of which might be improved by the discovery and use of noninvasive proteomic biomarkers.

Proteomic technologies, such as those based on mass spectrometry, protein microarrays, and developing methodologies like metabolomics, lipidomics, and proteogenomics, have made it possible to conduct an in-depth examination of the proteome and to identify protein signatures that are related with illness. These biomarkers have the benefit of not requiring invasive procedures, which paves the way for more regular monitoring and reduces the need for invasive operations like liver biopsies.

Validation and standardization must be carried out in an exacting manner prior to the clinical translation of proteomic biomarkers in NAFLD. In order to prove the therapeutic value of these biomarkers and the predictive capacity they possess, large-scale validation studies that include a variety of patient groups are very necessary. It is necessary to have standardized procedures, reliable assay platforms, and data analysis processes in order to guarantee the reproducibility and comparability of findings obtained from various labs.

The heterogeneity of NAFLD, the restricted sample availability, repeatability concerns, and the need for biomarker panels and algorithms are some of the hurdles and limits that need to be solved before effective clinical application may occur. In addition, ensuring the broad use of proteomic biomarkers in ordinary clinical practice requires taking into account how cost-effective they are and how easily they can be accessed.

In spite of these difficulties, the current developments in proteome technology, multi-omics integration, and machine learning approaches provide potential paths for overcoming constraints and aiding the clinical translation of proteomic biomarkers. It is possible that the incorporation of proteomic biomarkers into clinical practice may enhance the treatment of NAFLD, make it possible to take customized medicine methods, and lessen the strain on healthcare systems.

In conclusion, noninvasive proteomic biomarkers have a great deal of potential to revolutionize the diagnosis, staging, prognosis, and treatment monitoring of nonalcoholic fatty liver disease (NAFLD). In order to overcome obstacles and reach the full potential of proteomic biomarkers in NAFLD, further research, validation studies, and partnerships between researchers, clinicians, and industry stakeholders are required. Individuals who are afflicted with NAFLD may see improved results if sustained attempts are made to incorporate proteomic biomarkers, which may enhance patient care, guide choices about therapy, and improve outcomes.

Acknowledgement: *The authors are grateful to the Deanship of Scientific Research, Prince Sattam bin Abdulaziz University, Al-Kharj for this research work.*

REFERENCES

1. *Ahn SB, Jun DW, Kang BK., et al (2010).* Serum proteomic analysis for discovery of hepatocellular carcinoma biomarkers. J Hepatol. 52(4): 595-604 DOI: 10.4254/wjh.v2.i3.127
2. *Anstee QM, Targher G, Day CP (2013).* Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 10(6): 330-344 DOI: 10.1038/nrgastro.2013.41
3. *Bessone F, Razori MV, Roma MG (2019).* Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 76(1): 99-128 DOI: 10.1007/s00018-018-2947-0
4. *Buzzetti E, Pinzani M, Tsochatzis EA (2016).* The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 65(8): 1038-1048 DOI: 10.1016/j.metabol.2015.12.012
5. *Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K., et al (2018*). The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 67(1): 328-357 DOI: 10.1002/hep.29367
6. *Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B., et al (2009).* Differential expression of lumican and fatty acid binding protein-1: New insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology. 49(4): 1375-1384 DOI: 10.1002/hep.22927
7. *Cui J, Philo L, Nguyen P., et al (2015).* Serum metabolome and lipidome changes in adult

patients with primary biliary cirrhosis. PLoS One. 10(9): e0136900 DOI: 10.1111/liv.12680

8. *DiStefano JK, Kingsley C, Craig Wood G., et al. (2018).* A predictive model of NAFLD risk in overweight and obese adolescents. J Hepatol. 68(1): 64-72 DOI: 10.2147/DMSO.S146339
9. *Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P (2017).* Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism. 71: 182-197 DOI: 10.1016/j.metabol.2017.03.013
10. *Eslam M, Sanyal AJ, George J (2020).* International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 158(7): 1999-2014 DOI: 10.1053/j.gastro.2019.11.312
11. *Gentile CL, Frye M, Pagliassotti MJ (2011).* Endoplasmic Reticulum Stress and the Unfolded Protein Response in Nonalcoholic Fatty Liver Disease. Antioxidants & Redox Signaling. 15(2): 505-521 DOI: 10.1089/ars.2010.3790
12. *Geyer PE, Holdt LM, Teupser D, Mann M (2017).* Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol. 13(9): 942 DOI: 10.15252/msb.20156297
13. *Li Z, Wang X, Yang Z., et al. (2020).* Proteomics in non-alcoholic fatty liver disease: new insights into disease mechanisms and potential biomarkers. Frontiers in Cellular and Infection Microbiology. 10: 135 DOI: 10.3390/nu12092762
14. *Li Z, Wang Y, Li Y., et al (2020).* The diagnostic and prognostic role of long non-coding RNA NEAT1 in patients with nonalcoholic fatty liver disease. Aging (Albany NY). 12(6): 5281-5297 DOI: 10.2147/CMAR.S269978
15. *Li Z, Zhang X, Yang Z., et al (2020).* Identification of novel urinary biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis in a Chinese cohort. Hepatology. 72(1): 208-221 DOI: 10.3390/ijms24032844
16. *Liu Y, Zheng D, Liu M, Bai Y, Yu H, Chen S., et al (2019).* Novel insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharide (LPS) and adipose tissue inflammation. Front Physiol. 10: 1152 DOI: 10.3390/nu12092762
17. *Machado MV, Michelotti GA, Pereira TA, Kruger L, Swiderska-Syn M., et al (2015).* Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. Gut. 64(7): 1148-1157
18. *Mantovani A, Byrne CD, Bonora E, Targher G (2018).* Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 41(2): 372-382 DOI: 10.2337/dc17-1902
19. *Neuman MG, Cohen LB, Nanau RM (2014).* Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. 28(11): 607-618 DOI: 10.1155/2014/757929
20. *Povero D, Panera N, Eguchi A, Johnson CD, Papouchado BG, de Araujo Horcel L., et al (2015).* Lipid-Induced Hepatocyte-Derived Extracellular Vesicles Regulate Hepatic Stellate Cell via MicroRNAs Targeting Peroxisome Proliferator-Activated Receptor-γ. CMGH Cellular and Molecular Gastroenterology and Hepatology. DOI: 10.1016/j.jcmgh.2015.07.007
21. *Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P., et al (2005).* Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease. 128(7): 1898-1906 DOI: 10.1053/j.gastro.2005.03.084
22. *Targher G, Lonardo A, Byrne CD (2018).* Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 14(2): 99-114 DOI: 10.1038/nrendo.2017.173
23. *Wang X, Cao Y, Wang Y., et al (2018).* Nonalcoholic fatty liver disease: molecular imaging and therapeutic targets. Front Pharmacol. 9: 521 DOI: 10.3389/fendo.2022.1002916
24. *Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016).* Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64(1): 73-84 DOI: 10.1002/hep.28431
25. *Zhou X, Cai D (2016).* Endoplasmic reticulum stress and unfolded protein response in nonalcoholic fatty liver disease. Protein Cell. 7(9): 490-500 DOI: 10.1146/annurev-nutr-071811-150644

THE NEW ARMENIAN MEDICAL JOURNAL
Volume18 (2024), Issue 3 p. 68-81

DOI: https://doi.org/10.56936/18290825-3.v18.2024-68

THE ROLE OF EVOLVING TECHNIQUES AND PROSPECTIVE IMPLICATIONS OF BIOMARKERS IN LIVER DISEASE

Bari Md. N., Ansari Md.R., Alfaki M.A.,

Department of Basic Medical Sciences, College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.

Received 05.10.2023 Accepted for printing 04.08.2024

Abstract

Wounds that influence the liver are shockingly normal in more youthful individuals. This condition might introduce itself clinically as subclinical hepatitis, intense hepatitis, persistent hepatitis, remunerated liver constant infection, decompensated liver cirrhosis, intense liver disappointment, or intense on persistent liver disappointment. These indications are possible. A liver capability test would frequently take a gander at various different biochemical markers, including complete bilirubin, direct bilirubin, Serum glutamic oxaloacetic transaminase, Serum glutamate pyruvate transaminase, egg whites, supportive of thrombin time, and gamma-glutamyl transferase.

Novel biomarkers are presently effectively accessible as an immediate outcome of current specialized leap forwards and applications. The utilization of creature models is the beginning stage for the examination of these biomarkers, with the concentrate then, at that point, moving to human subjects. They can offer data that is demonstrative as well as data about the visualization. They give some enlightening data on the histological condition of the liver. Notwithstanding, they are restricted by the circumstances that they think of themselves as in. By directing an examination of marks of liver harm in youngsters, this exploration shows new conceivable outcomes and philosophies for the determination of liver sickness in kids. Concentrates on that focus on individual biomarkers as a restorative place of section are something that might be plausible to investigate not long from now. Hepatology is a subspecialty that is still during the time spent developing, and one of its subspecialties is the investigation of biomarkers. The developing weight of worldwide liver sickness, the shortfall of side effects until late in the regular history of an illness that might require a very long time to show, the presence of an obtrusive reference test (liver biopsy) to evaluate infection seriousness, and the absence of powerful instruments to survey the viability of restorative mediations are a portion of the critical drivers for this exploration.

Furthermore, the shortfall of side effects until late in the regular history of a sickness that might require a very long time to show is one more key driver for this examination.

Moreover, one of the essential motivations behind why this study is being directed is because of the deficiency of dependable instruments with which to assess the viability of restorative methodologies.

Keywords: *biomarker, cytokeratin 18, leucocyte cell derived chemokine 2, liver specific micro RNAS, exosomes*

Cite This Article as:

Bari Md. N., Ansari Md.R., Alfaki M.A. (2024). The role of evolving techniques and prospective implications of biomarkers in liver disease: A systematic review, The New Armenian Medical Journal, vol.18(2), 68-81; https://doi.org/ 10.56936/18290825-3.v18.2024-68

Address for Correspondence:

Nadeem Bari, MD
Department of Basic Medical Sciences, College of Medicine, Prince Sattam bin Abdulaziz University
Al-Kharj 11942, Saudi Arabia,
Tel.: +966509280389
E-mail: nadeembari273@gmail.com

Introduction

The examination of biomarkers is a part of Hepatology that is as yet creating. The developing weight of worldwide liver sickness, the shortfall of side effects until late in the regular history of an illness that might require a very long time to show, the presence of an obtrusive reference test (liver biopsy) to evaluate infection seriousness, and the absence of powerful apparatuses to survey the viability of restorative mediations are a portion of the critical drivers for this exploration. Furthermore, one of the critical drivers for this exploration is the way that there is an absence of vigorous instruments to evaluate the viability of restorative intercessions.

A biomarker is "A characteristic that is dependably tried and evaluated as a sign of typical biologic cycles, pathogenic cycles, or pharmacologic reactions to a restorative intercession", as indicated by the Public Establishments of Wellbeing's definition [*Atkinson J et al., 2001*]. Furthermore, biomarkers can be coordinated into various leveled frameworks as indicated by their ability to assess regular history (type 0: visualization), organic movement (type 1: reaction to treatment), and restorative viability (type 2: intermediary for clinical adequacy) [*Mildvan D et al., 1997*].

The range of obsessive wounds that might create because of liver infection, for example, steatosis, necroinflammation, apoptosis, and fibrosis, adds to an expanded pool of conceivable biomarkers. What's more, the improvement of new mechanical stages has prompted an outstanding expansion in the quantity of expected middle people of pathophysiological hurt that have been found. This has been counterbalanced by the rising need to coordinate substitute marks of harm with clinical outcomes of injury to accomplish demonstrative, prognostic, and restorative viability. This is fundamental to accomplish demonstrative, visualization, and restorative achievement. This convenient extraordinary issue is contained unique examinations as well as surveys in the subject areas of biomarker revelation, biomarkers of liver harm, and biomarkers to assess the repercussions of liver injury.

Methods of biomarker discovery: The improvement of better instruments has been a main impetus behind the distinguishing proof of biomarkers. Enormous scope omics biomarker revelation projects were driven by the improvement of present day organic mass spectroscopic procedures during the 1990s and the development of two-layered polyacrylamide gel electrophoresis, otherwise called 2D SDS PAGE, from an exceptionally particular strategy to one that could be completed in many research facilities all over the planet. Further driving force was added to this line of concentrate by the advancement of high-performance liquid chromatography frameworks with microliter stream rates that could be associated straightforwardly to mass spectrometers (nano- liquid chromatography/mass spectrometry) and PCs to investigate the information. Inside the extent of a solitary investigation, it is presently plausible to quantify and distinguish a large number of proteins extricated from debilitated as well as solid tissue. The ability to distinguish new signs of liver sickness has been shown by biomarker revelation endeavors [*Barr J et al., 2010*] metabolomics; [*Puri P et al.,* 2009] lipid omics; [*Bell L et al., 2010*] proteomics; [*Younossi et al., 2005*] Surface-Enhanced Laser Desorption/Ionization and transcriptomic). The disciplines of proteomics, transcriptomic, lipid omics, and metabolomics all give the potential chance to distinguish completely one of a kind infection pointers and the course of sickness. This once more technique for biomarker improvement eventually brings about a critical obstruction as marker approval. It is conceivable that there is practically zero obvious unthinking connection between the putative marker and the sickness, which exhibits that laying out a connection could require a critical speculation of both time and assets.

Finding biomarkers utilizing a component driven approach has likewise profited from improvements in the plan and innovation of instruments. These examinations are predicated on recently procured data on the sickness; their extension is significantly more compelled, however if they are effective, there is a bigger potential of tracking down an infection pertinent marker. Standard enzyme linked immune sorbent assay test methodology have been laid out to utilize valuable patient examples by empowering the synchronous measurement of an enormous number of analyses. In an exhibit or planar test, various essential antibodies are fastened to a surface as discrete spots. Then, an example, an optional immune response,

and identification reagents are moved over the cluster. At long last, the place of the sign is distinguished utilizing imaging innovation. Globule put together strategies depend with respect to a blend of immune response marked dots, which are in this manner estimated utilizing stream cytometers or other particular analyzers. Utilizing boards of antibodies that have been streamlined to limit cross-reactivity, it is feasible to break down somewhere in the range of 30 to 50 distinct proteins in a solitary examination. While directing compound movement based biomarker disclosure, scaling down of fluid taking care of and high-thickness microplates, which can by and by hold up to 1536 examples for every plate, brings about a decrease in how much reagent and patient example utilization. The high thickness of a standard 96-well microplate will require the utilization of 100 L of response blend per well, though 1536-well plates call for only 5 L for every well, addressing a diminishing in example utilization that is multiple times more noteworthy. Unfortunately, the additional costs that should be borne to ensure right reagent administration and response observing are not inconsequential. In this issue, S. K. Hartwell subtleties another technique that utilizes stream infusion to decrease how much reagent required in circumstances in which the quantity of tests and volume of tests might be confined. The utilization of research facility hardware that is effectively available is urged to eliminate costs and make the innovation more open to foundations who have less assets.

Biomarkers of liver injury: There are different circumstances that might influence the liver, however the obsessive cycles of steatosis, necro inflammation, oxidative pressure, apoptosis, and fibrosis are available in every one of them. While evaluating the unthinking proof of viability for recommended treatment choices using biomarkers, it is useful to have the ability to describe these different substances. The way that the obsessive cycles are much of the time dependent on each other or corresponded keeps on being a test, and subsequently, distinguishing biomarkers that are extraordinary to a solitary sort of harm might be troublesome. This is shown by the paper composed by N. Mousa and associates that is remembered for this extraordinary issue. It talks about the association between alpha fetoprotein and liver steatosis with regards to genotype 4 contamination in persistent viral hepatitis. The creators have a speculation that the raised degrees of alfa fetoprotein are because of an expansion underway from hepatic begetter cells as a response to the recovery that happens after a physical issue. In this exploration, steatosis was additionally associated with the presence of necro inflammation and fibrosis. Subsequently, it is muddled whether the seriousness of liver harm or steatosis fundamentally is answerable for the ascent in Alfa fetoprotein. Steatosis was related with the presence of necro inflammation and fibrosis. Whether harmless steatosis (without even a trace of extreme steatohepatitis or fibrosis) has any clinical significance is the subject of a continuous conversation in clinical writing. In instances of viral hepatitis, steatosis is all the more frequently found in contaminations with the genotype 3 infection, and it further develops once popular annihilation is achieved [*Castera L et al., 2004*]. Steatosis has not been demonstrated to unfavorably affect the result of nonalcoholic greasy liver sickness in long haul examinations that depend on the obsessive qualities present at the hour of the benchmark biopsy [*Teli M, 1995; Sooderberg J et al., 2010*]. Regular history studies have exhibited that the presence of fibrosis at the record liver biopsy, as well as the phase of fibrosis around then, could give prescient data about the later pace of fibrosis movement [*Yano M et al., 1996, Poynard T et al., 1997; Matteoni A, 1999*] .and the advancement of liver-related occasions [*Lawson A et al., 2007*]. It ought to in this manner shock no one that, throughout the span of the last ten years, a lot of consideration has been put on the improvement of new biomarkers in light of the presence of obsessive fibrosis. The benefits as well as the disadvantages of utilizing this technique have been talked about somewhere else [*Castera L, 2012*]. There are various motivations behind why characterizing substitutes for different clinical circumstances than liver fibrosis isn't just significant yet additionally valuable. Different hepatic wounds might prompt fibrosis of the liver, which is fundamentally an injury recuperating response and a definitive well known course that outcomes from many attacks. Furthermore, the organization of compelling ant fibrotic prescription has been trou-

blesome in the past because of extraordinary properties of the hepatic scar. These attributes incorporate the organization as well as the physical and biochemical characteristics that confine redesigning and angioarchitectural modifications. On the off chance that it is feasible to mediate "upstream" during the time spent harm, this might bring about a more noteworthy repertory of restorative choices, each with the potential for improved focusing on and greater medication profiles. It's conceivable that apoptosis in the liver is one such model. In preclinical models, the goal of fibrosis is reliant upon the evacuation of actuated hepatic stellate cells through the course of apoptosis. This is notwithstanding the way that the engulfment of apoptotic bodies by initiated hepatic stellate cells (HSCs) may instigate transforming growth factor and collagen-1 amalgamation and advance fibrosis. In this manner, the far reaching portrayal of apoptosis might give significant bits of knowledge into both the course of fibrinolysis and the improvement of fibrosis. In this extraordinary version, J. B. Chakraborty, and partners present an exhaustive survey of the components of apoptosis in the liver, up-and-comer apoptosis-related biomarkers, and the potential for clinical interpretation (for instance, evaluating treatment reaction as well as observing the relapse of fibrosis).

Pathogenesis of liver diseases: As an outcome of the way that liver infection influences a large number of individuals and is answerable for around 1.2 million passings every year, it is a significant supporter of the worldwide weight of sickness [*Sooderberg C et al, 2010*]. Contaminations with the hepatitis B or C infections (viral hepatitis), unreasonable liquor utilization (adrenoleukodystrophy); alcoholic steatohepatitis (Debris); or alcoholic hepatitis; and metabolic problems (non-alcoholic fatty liver disease or non-alcoholic steatohepatitis) are the most widely recognized reasons for liver infections. [*Yano M et al, 1996*]. Other less successive causes incorporate medication glut drug-instigated liver injury, immune system sicknesses (primary biliary cholangitis), and hereditary variables (hemochromatosis, or Wilson's infection, for instance). [*Poynard T, 1997*]. Both non-alcoholic fatty liver disease and adrenoleukodystrophy are among the most successive reasons for persistent liver illness all around the world. Both non-alcoholic fatty liver disease and adrenoleukodystrophy display a practically identical range of pathologies, which might go from steatosis and steatohepatitis to fibrosis, cirrhosis, or potentially hepatocellular carcinoma (otherwise called liver malignant growth) [*Matteoni C, 1999*]. Cirrhosis of the liver is the most predominant and high level phase of liver infection, which might create from a wide assortment of causes.

The final product of hepatocellular injury, aggravation, and fibrosis in the liver is either liver cirrhosis or hepatocellular carcinoma. Persistent openness to affronts, for example, hepatotoxins, causes hepatocytes to go through apoptosis and putrefaction. This cycle brings about the discharge of responsive oxygen species and proinflammatory development variables, cytokines, and chemokines. A portion of these development factors incorporate platelet-determined development factor, vascular endothelial development factor, connective tissue development factor, and changing development factor-T. This discharge of proinflammatory substances causes the enlistment and enactment of neighborhood and attacking resistant cells, especially macrophages (occupant KCs and coursing monocytes), which eventually brings about persistent irritation of the liver. The insusceptible cells are answerable for the discharge of pro inflammatory and profibrogenic substances, which initiate lethargic HSCs and lead to an over the top development of extracellular framework as well as a deficiency of liver capability and engineering [*Lawson A, 2007 Castera L, 2012*]. Initiated HSCs are fundamentally to fault for the expanded testimony of extracellular matrix (ECM). These cells are answerable for delivering over the top amounts of ECM parts, fundamentally collagen-I (col-I) and - III (col-III), as well as tissue inhibitors of metalloproteinase, while at the same time smothering the discharge of matrix metalloproteinase (MMPs) [*Yano Teli M, 1995; M et al., 1996; Poynard T, 1997; Matteoni C, 1999; Castera L et al., 2004; Younossi Z et al., 2005; Lawson A et al., 2007; Bell L et al., 2010; Sooderberg C et al., 2010; Parkes J et al., 2011; Castera L, 2012*]. Furthermore, entrance fibroblasts add to an over the top development of extracellular framework, for the most part by the creation of collagen, especially in instances of cholestatic fibrosis [*Ngo Y et al., 2006; Parkes J et al., 2011; Vergniol J et al., 2011*].

Persistent liver harm, then again, quite often comes full circle in long-lasting and moderate cirrhosis [*Rincon D et al., 2007*]. Intense liver injury,

then again, may for the most part be turned around. Based on discoveries from rehashed biopsies performed on patients, it has been shown that gentle to direct fibrosis might be turned around, and this may be because of collagen crosslinks. At the point when cirrhosis creates, an unusually high measure of collagen is stored in the tissue, and over the top development of crosslinks prompts critical scarring and an irreversible loss of tissue flexibility [*Ripoll C et al., 2012*]. Hematologists have accomplished significant steps in sickness information, illness observing, and infection the executives throughout the span of the past couple of many years. Outstandingly, with regards to viral hepatitis, the disclosure and portrayal of hepatitis infections prompted the improvement of preventive treatments like immunizations, antiviral treatments, and immunomodulatory treatments. Subsequently, clinical medicines are currently accessible for hepatitis B virus and hepatitis C virus -driven liver sicknesses [*Forde K, Reddy K, 2009; El-Serag H, 2011*]. Notwithstanding, there are as yet two significant issues that should be fixed: one is the absence of a painless, definite, and early determination (otherwise called infection organizing), and the other is the absence of a productive treatment for liver sicknesses. Both of these issues presently can't seem to be survived. Be that as it may, the reasonableness of transplantation is confined inferable from a predetermined number of qualified contributor organs and different dangers and outcomes related with liver transplantation, including transfer dismissal, discharge, contaminations, and long haul immunosuppressant's [*Blachier M et al., 2013; Bansal R, 2016; Goldberg D, 2017*]. Notwithstanding, different treatments that to a great extent focus on tending to the fundamental reason are insufficient for cutting edge fibrosis [*Yano M et al., 1996; Poynard T, 1997; Matteoni C, 1999; Ngo Y et al., 2006; Lawson A et al., 2007; Rincon C et al., 2007; Forde K, Reddy K, 2009; El-Serag H, 2011; Parkes J et al., 2011; Vergniol J et al., 2011; Castera L, 2012; Ripoll C et al., 2012; Blachier M et al., 2013; Bansal R, 2016; Goldberg D et al., 2017; Du C et al., 2018*]. This remembers a diminishing for liquor use in adrenoleukodystrophy or a solid eating regimen in non-alcoholic fatty liver disease, the two of which might postpone the course of beginning phase fibrosis or even converse it.

Matrix metalloproteinases and their role in liver disease: Matrix metalloproteinase are an individual from the enormous metzincin superfamily, which is contained four subfamilies: matrix ins (MMPs), astracins (bone morphogenetic protein 1/tolloid-like protein 1, Bone Morphogenetic Protein 1 and Tolloid-like proteins or procollagen C-endopeptidases and meprins), bacterial serralysins, and adamalysins (disintegrin metalloproteinase), matrix metalloproteinase otherwise called matrixins, are calcium-subordinate endoproteinases that contain zinc and are answerable for debasing parts of the extracellular framework extracellular matrix, directing the trustworthiness and structure of the ECM, and having a huge impact in ECM-interceded flagging [*Puri P et al., 2009*]. Serine proteinases like as plasmin and cathepsin G, notwithstanding MMPs, disintegrin metalloproteinase, and A-disintegrin-like and metalloproteinase with thrombospondin motif, are accomplished in the debasement of ECM protein parts and are in this manner embroiled in ECM redesigning [*Lu P, 2011*].

Notwithstanding parts of the ECM, MMPs can separate cell surface particles as well as per cellular nonmatrix proteins, which permits them to control the way of behaving of cells [*Sternlicht M, Werb Z, 2001*]. Furthermore, MMPs can separate a great many other administrative particles, like serine protease inhibitors, cytokines, and chemokines; subsequently, they assume a part in various different formative cycles, including trophoblast implantation, embryogenesis, bone development, wound recuperating, and tissue recovery [*Flannery C, 2006.*]. Matrix metalloproteinases, taken in general, are answerable for the guideline of principal cell cycles like multiplication, separation, relocation, attachment, and passing [*Puri P et al., 2009*]. There has been a sum of 25 unmistakable MMPs found in vertebrates as yet, 24 of which have been tracked down in people. MMP-1 was the principal framework metalloproteinase and was demonstrated to be associated with the obliteration of the collagen triple helix during the course of fledgling tail transformation [*Gross J, 1962*]. MMP-1 was found in 1962 by Jerome Gross and Charles Lapiere. MMPs have been displayed to play a part in different physiological cycles, including bone redesigning, brain improvement, nat-

ural and versatile immunological reactions, irritation, and angiogenesis [*Löffek S et al., 2011*]. As a result of the flexibility of their capabilities, MMPs and tissue inhibitors of metalloproteinase have been connected to a wide assortment of sicknesses, for example, provocative and fibrotic infections, joint inflammation, cardiovascular problems, malignant growth, and metastases [*Chuang H et al., 2019*]. Different sicknesses connected to MMPs and tissue inhibitors of metalloproteinase incorporate joint inflammation and cardiovascular problems.

Based on their substrate particularity and homology, human MMPs might be isolated into the accompanying six fundamental gatherings: I collagenases (MMP-1, - 8, - 13); (ii) stromelysins (MMP-3, - 10, - 11, - 17); (iii) gelatinases (MMP-2, - 9); (iv) matrilysins (MMP-7, - 26); (v) layer type MMPs The consequences of genomic studies have shown that there are 24 separate qualities that each code for an alternate MMP. Matrix metalloproteinases can be isolated into different gatherings, as displayed in Figure 1, based on the underlying variety that they show. (a) Prototype MMPs, which are made out of collagenases (MMP-1, - 8, and-13), stromelysins (MMP-3, and-10), and extra MMPs (MMP-12, - 19, - 20, - 22, - 27). An exceptionally moderated hemopexin space that guarantees substrate particularity and collaboration with endogenous inhibitors, a synergist space containing two zinc particles (Zn2+) and something like one calcium particle (Ca2+), a pivot joining the reactant and hemopexin spaces, an amino-terminal supportive of peptide to keep up with catalyst dormancy, and a sign peptide that coordinates discharge from the cells are the unmistakable underlying spaces that are available in (b) Gelatinases, like MMP-2 and MMP-9, have a fibronectin space and have a construction that is like that of the prototypical MMP. (c) Matrilysins (MMP-7, - 26) have a design that is practically identical to that of prototype MMPs, however they don't have a hemopexin space. (d) Like prototype MMPs in structure, emitted MMPs (MMP-11, - 21, - 28) have a furin-like cleavable space and look like original MMPs in different regards. (e) Layer type MMPs, like MMP-14, MMP-15, MMP-16, and MMP-24,



Figure 1. Domain structure diversity of human matrix metalloproteinases (MMPs), displayed as a schematic overview of different human MMPs categorized into groups based on their domain structure: (a) collagenases; (b) gelatinases; (c) matrilysins; (d) secreted MMPs; (e) membrane-type MMPs with transmembrane domains, C-terminal TM-1 and cytoplasmic tail; (f) membrane-type MMPs with C-terminal glycosylphosphatidylinositol anchor; and (g) other MMPs with N-terminal transmembrane domain-II (TM-II) and cytoplasmic c-terminal immunoglobulin-like cell adhesion molecule (Ig-CAM). Zn2+, zinc ions [. [*Geervliet E., Bansal R. 2020*]]

are found at the cell surface and are undifferentiated from run of the mill MMPs. They incorporate a furin-like cleavable space notwithstanding transmembrane spaces, which incorporate a C-terminal TM-1 and a cytoplasmic tail. (f) Layer type MMPs, like MMP-17 and MMP-25, are like prototype MMPs and highlight a C-terminal glycosylphosphatidylinositol layer anchor. (g) Other MMPs (MMP-23A and MMP-23B), which in like manner look like prototype MMPs however don't have a hemopexin space and on second thought have a N-terminal TM-II space and a cytoplasmic C-terminal immunoglobulin-like cell bond particle (Ig-CAM) space [34,35], are called MMP-23A and MMP-23B, separately.

Most of MMPs are discharged as supportive of catalysts, which are then actuated in the extracellular space after they have been delivered. Different cell types in the body, including as epithelial cells, fibroblasts, endothelial cells, and provocative cells like monocytes, macrophages, and neutrophils, are answerable for their creation. They have been connected to different physiological and obsessive cycles [*Cui N et al., 2017*]. In the liver, every single hepatic cell, for example, hepatocytes, HSCs, hepatic macrophages (counting occupant KCs and penetrated monocyte-determined macrophages), and penetrated leukocytes, are equipped for delivering MMPs; be that as it may, among these, HSCs are the significant makers [*Iredale J, 1997; Consolo M et al., 2009*]. Hepatocytes are one more sort of hepatic cell that is equipped for delivering MMPs Different framework metalloproteases (MMPs) have been displayed to play a part in the turn of events, movement, and fix of liver problems [*Castera L et al., 2004; Bell L et al., 2010; Roeb E, 2018*]. Metalloproteases are perceived to be locked in at many periods of liver sicknesses, including liver harm, aggravation, fibrosis, cirrhosis, and hepatocarcinogenesis, as well as illness goal and liver recovery, notwithstanding the way that the fundamental cycles remain for the most part muddled (Fig. 2). Metalloproteases have additionally been researched as "direct" (reflecting ECM turnover) and 'roundabout' (particles delivered into the blood that reflect unusual hepatic ca-



Figure 2. The role of different MMPs in the progression of liver diseases. Liver inflammation is induced by MMP-3, -8, -9, -10, -12, -13 and -14. These MMPs are involved in the degradation of normal ECM and the release of chemotactic cytokines that initiate macrophage and leukocyte infiltration and activation. MMP-7, -9, -10, -12, -16 and -19 are involved in fibrosis progression and ECM remodeling. When fibrosis is established, it can either be resolved directly by activation of ECM-degrading MMPs, such as MMP-1, -2, -8 and -13, or indirectly by MMP-10 and -24, or can lead to hepatocellular carcinoma regulated by MMP-2, -3, -7, -8, -9, -10, -11, -12, -13, -14, -16 and -28. hepatocellular carcinoma metastasis is a complex cascade consisting of endothelial-to-mesenchymal transition (EMT) and proliferation (MMP-3, -9, -11 and -12), invasion (MMP-2, -3, -8, -9, -10, -13, -14, -16 and -28), angiogenesis (MMP-9 and -10) and intravasation (MMP-2, -3, -7, -8, -9, -10, -11 and -14) into the bloodstream and extravasation (MMP-2, -3, -7, -9, -10, -11, -13, -14, -16 and -28) into other tissues. [Geervliet E., Bansal R. 2020]

pability) biomarkers for precise determination and organizing of liver fibrosis. This is on the grounds that the declaration of various MMPs fluctuates relying upon the phase of the infection. In the accompanying, numerous unmistakable MMPs will each be examined corresponding to their capability as a biomarker and their cooperation in a specific liver sickness.

Metalloprotease-1, which is otherwise called collagenase-1, separates both extracellular framework and non-ECM substrates, including collagen, gelatin, laminin, supplement C1q, interleukin 1 beta (IL-1), and cancer putrefaction factor alpha tumor necrosis factor (TNF-). Subsequently, it assumes a significant part in the cycles of fibrosis and aggravation. Col-I and col-III are the most bountiful proteins in a fibrotic liver, and MMP-1 has serious areas of strength for a for themselves and the capacity to obliterate them too. Furthermore, MMP-1 is equipped for initiating MMP-2 and MMP-9. MMP-1 is fundamentally communicated by HSCs and maybe by provocative cells (like pole cells, KCs, and monocytes) in the liver [*Castera L et al., 2004*]. This declaration of MMP-1 is viewed as constitutive in ordinary livers. In people with persistent hepatitis C disease, it was found that MMP-1 serum levels had a backwards relationship to the seriousness of the sickness [*Murawaki Y et al., 2002*]. In patients with persistent hepatitis C disease, the blend of col-III/MMP-1 proportion cardiovascular magnetic resonance, alpha-fetoprotein, aspartate aminotransferase/alanine aminotransferase proportion, and platelet count has been recommended for F2-F4 organizing of fibrosis [*Attallah A et al., 2015*]. This idea depends on the outcomes. There seems, by all accounts, to be a backwards relationship between MMP-1 levels and the movement of fibrosis in non-alcoholic steatohepatitis patients, as it has been seen that an expanded articulation of MMP-1 in monocytes, KCs, and hepatic stellate cells has been seen in early non-alcoholic steatohepatitis in non-alcoholic steatohepatitis patients, however not in that frame of mind in non-alcoholic steatohepatitis patients [*Ando W et al., 2018*]. Metalloprotease-1 serum levels were displayed to have serious areas of strength for a with beginning phases of fibrosis (necro inflammation and fibro inflammation) in people with non-alcoholic steatohepatitis and persistent hepatitis C disease; be that as it may, no relationship was found between MMP-1 serum levels and later phases of fibrosis [*Ando W et al., 2018*]. Metalloprotease-1 allelic polymorphism has likewise been recommended as a potential supporter of the improvement of hepatocellular carcinoma [*Zhou Z, 2018.*]. Cells 2020, 9, x FOR Companion Survey 5 of 20 In the liver, every single hepatic cell, for example, hepatocytes, hepatic stellate cells, hepatic macrophages (counting local KCs and penetrating monocyte-determined macrophages), and penetrated leukocytes, are equipped for delivering MMPs; be that as it may, among these, HSCs are the overwhelming makers [*Iredale J, 1997; Consolo M, 2009*]. 5 of 20 Different framework metalloproteases (MMPs) have been displayed to play a part in the turn of events, movement, and fix of liver problems [*Castera L et al., 2004; Puri P et al., 2009; Roeb E, 2018*]. MMPs are perceived to be locked in at many periods of liver sicknesses, including liver harm, aggravation, fibrosis, cirrhosis, and hepatocarcinogenesis, as well as illness goal and liver recovery, notwithstanding the way that the fundamental cycles remain for the most part muddled (Fig. 2). MMPs have additionally been researched as “direct” (reflecting ECM turnover) and “circuitous” (particles delivered into the blood that reflect strange hepatic capability) biomarkers for precise determination and organizing of liver fibrosis. This is on the grounds that the declaration of various MMPs fluctuates relying upon the phase of the infection.

Matrix metalloproteinases as therapeutic targets: Be that as it may, unusual dysregulation of MMP articulation and additionally movement has been exhibited to straightforwardly or in a roundabout way add to the progression of liver problems. This is notwithstanding the way that MMPs assume a basic part in the Extracellular matrix redesigning that happens during ordinary physiology. An assortment of MMPs is participated in the different stages, with their demeanor contrasting between intense liver harm, hepatic irritation, fibrosis/cirrhosis, and hepatocellular carcinoma; likewise, certain MMPs are associated with the goal of the sickness (Fig. 2). The exercises of unmistakable MMPs in liver sicknesses were found by preclinical creature research that pre-owned quality explicit MMP knockout crea-

ture models. These investigations gave understanding into the fundamental cycles of specific MMPs. What's more, clinical examination has offered bits of knowledge into the levels of their demeanor in different liver sicknesses. Notwithstanding, albeit by far most of exploration are coordinated toward a superior comprehension of the job that MMPs play in the development of liver sickness, not very many examinations have been coordinated toward the fix or treatment of liver problems. In this article, we will go through the examination that has been finished on MMPs to see whether they might be utilized as forthcoming restorative focuses in the treatment of liver sicknesses.

There are at least one or two MMPs that are equipped for corrupting fibrillary collagens. Among these MMPs, the collagenases, which incorporate MMP-1, MMP-8, and MMP-13, are the most impressive MMPs. It has been exhibited to be an exceptionally encouraging technique in different exploratory creature models to regulate MMP-1 determined to fix liver sicknesses, which has been the subject of a lot of examination and examination. Iimuro et al. (2003) uncovered in 2003 that adenoviral-vector-intervened organization of human supportive of MMP-1 (Ad5MMP-1) moderated laid out liver fibrosis in a long haul thoracic aortic aneurysm - prompted liver fibrosis rodent model. This worldview was utilized to concentrate on liver fibrosis brought about by thioacetamide. The creators of this work found that intravenous conveyance of Ad5MMP-1 came about in intrahepatic supportive of MMP1 articulation as well as MMP-1 movement. These discoveries give proof that supportive of MMP1 was successfully changed into the dynamic structure in vivo. Subsequently, following fourteen days of treatment with Ad-5MMP-1, fibrosis was improved, and this improvement was kept up with for four extra weeks. Fundamentally, the corruption of extracellular framework (ECM) that was instigated by MMP-1 conveyance was joined by the hindrance, vanishing, or apoptosis of initiated HSCs. This, thusly, prompted a diminishing in the declaration of TIMP, which thusly decreased the collection of ECM, and an expansion in the multiplication of hepatocytes, which leaned toward liver recovery [*Iimuro Y et al., 2003.*]. As indicated by the discoveries of this examination, controlling MMP-1 as a treatment methodology to decrease liver fibrosis has significant restorative commitment. Then again, it is fundamental for remember that the utilization of viral vectors might bring about immunogenic and destructive outcomes. At the point when the vectors are utilized for a more drawn-out timeframe, there is plausible that they will instigate an unfortunate overexpression of MMPs. This can bring about antagonistic impacts, for example, the corruption of ordinary physiological ECM and expanded initiation of other MMPs. What's more, the vectors can possibly instigate an overexpression of MMPs (e.g., MMP2 is one of the objectives of MMP1 that initiates responsive oxygen species creation and in this manner could actuate aggravation).

In a different piece of examination, Du et al. (2018) concentrated on an alternate technique for MMP-1 organization, which incorporated the transplantation of bone-marrow-determined foundational microorganisms that were overexpressing MMP-1 (BMSCs/MMP-1). In this review, disconnected essential rodent BMSCs were transfected with a recombinant adenoviral vector containing human MMP-1 quality. These transfected cells were then relocated in a carbon tetrachloride (CCl4)- prompted rodent model of liver fibrosis [*Du C et al., 2018*]. The consequences of this study showed that the relocated cells diminished the seriousness of liver fibrosis in the CCl4-actuated model. The treatment with BMSCs and MMP-1 brought about brought down collagen levels and constricted HSCs enactment in fibrotic livers. This, thusly, drove in enhancement of liver harm and fibrosis, showing that BMSCs/MMP-1 is a promising ant fibrotic treatment for the goal of liver fibrosis. Be that as it may, there are a few intrinsic challenges related with the utilization of BMSCs. These challenges incorporate an intrusive methodology for disconnecting BMSCs, a low endurance rate and movement level of BMSCs, and an absence of a streamlined convention for the conveyance course or vulnerability with respect to the quantity of infusions. Itaba et al. as of late announced that orthotropic transplantation of IC-2 designed BMSCs sheets restrained persistent CCl4-instigated liver fibrosis by initiating creation of MMP-1 (and MMP-14 and thioredoxin), with resulting concealment of HSCs enactment. IC-2 is a subordinate of a Wnt/ - catenin inhibitor. MMP-1

enlistment by diethyldithiocarbamate, which was constrained by Akt and ERK/miR-222/ETS-1 pathways, was researched as an original instrument of MMP-1 guideline by Liu et al. in a different report. Their discoveries recommended that restraining miR-222 (which brought about MMP-1 enlistment) could be a possible restorative methodology for the treatment of liver fibrosis.

Notwithstanding MMP-1, adenoviral vectors have been researched for their capability to convey MMP-8. In rodent models of liver cirrhosis delivered by CCl4 and bile-conduit ligation, Garcia-Bauelos et al. investigated the restorative viability of adenoviral vector interceded organization of MMP-8 (AdMMP-8). The creators found that in vivo organization of AdMMP-8 came about in intrahepatic articulation of supportive of MMP-8 and its utilitarian dynamic structure. As an outcome, this brought about the inversion of fibrosis, alongside an improvement in liver capability tests and intrahepatic circulatory strain in both creature models. What's more, the researchers found that the declaration of transforming growth factor-mRNA was fundamentally diminished, while the statement of MMP-9 and HGF was essentially raised. The discoveries, taken together, highlighted AdMMP-8 as a possibly valuable ant fibrotic treatment. In a different piece of examination, Liu and partners researched the impacts, both in vitro and in vivo, of a combination protein called cMMP-8-1K1 that included MMP-8 and human hepatocyte development factor freak 1K1. cMMP-8-1K1 kept up with liver capability after a hepatectomy of 70%, invigorated hepatocyte multiplication and recovery, mitigated CCl4-prompted liver fibrosis, and was demonstrated to be compelling in treating these circumstances [*Okamoto K et al., 2005*].

Notwithstanding the way that MMPs have shown empowering brings about the preclinical models, none of the MMPs have been put through the afflictions of clinical testing as expected medicines for liver sicknesses. Then again, various clinical exploration has researched MMPs for their true capacity as biomarkers or potentially MMP genotype polymorphism for their job as a gamble calculate persistent liver problems like hepatocellular carcinoma and colorectal liver metastases. Prior to researching MMPs as possible restorative targets, getting a comprehension of the capability and component of MMPs corresponding to the movement of the illness is fundamental. MMPs and MMPIs, frequently known as MMP inhibitors, are the two possibility for utilization as potential prescriptions. Prior to building MMPI or MMP organization strategies, the accompanying worries ought to be borne as a primary concern, notwithstanding the way that MMPs address appealing and forthcoming restorative targets: I MMPs are related with typical physiologic cycles, like ovulation, trophoblast intrusion, and early stage advancement; (ii) extracellular matrix sections coming about because of MMP debasement are naturally dynamic and, subsequently, can likewise intercede optional impacts influencing both physiological and obsessive cycles; and (iii) MMPs are related with ordinary physiologic cycles, like ovulation, trophoblast intrusion, and undeveloped turn of events; (ii (iii) particularity and selectivity, unfortunate pharmacokinetics, portion restricting secondary effects/poisonousness, precariousness, and unfortunate bioavailability ought to be viewed as corresponding to MMPIs; (iv) MMPs assume a significant part in resistant cycles, explicitly, MMP-interceded cleavage enacts and restrains cytokines and chemokines; (v) expanded MMP articulation and movement have been obviously connected with malignant growth advancement and metastasis; (vi) MMP based on our current information on the pathophysiology of MMPs, as well as the significant proof that is accessible from clinical preliminaries on disease, creative procedures that target MMPs could possibly help to the fight against persistent liver problems that have neglected needs.

Conclusion

To give delineated care to patients who have liver infection, we desperately need harmless apparatuses that can successfully aggregate patients in light of the level of liver injury they have encountered, the regular history of their condition, and the clinical results they have encountered. It is unfathomable that the determination of a mediation for a particular patient yet, generally speaking, stays an observational activity including "experimentation". The objective of examination on biomarkers and the dissemination of that information ought to be to dispense with these obstructions

to individualizing treatment. Liver harm, which can be brought about by drinking an excessive amount of liquor, driving an unfortunate way of life, or being presented to other gamble factors, can ultimately prompt fibrosis, cirrhosis, and hepatocellular carcinoma. This condition influences a large number of individuals all over the planet and is the essential justification behind liver-related mortality and horribleness. Shockingly, there are no restoratively reasonable prescriptions accessible, and liver transplantation is the sole treatment choice for end-stage liver disappointment right now. The matrix metalloproteinase, which are fundamental middle people of liver problems, are brought into the spotlight in this review. Matrix metalloproteinase play a critical part not just in the first place and progression of a few liver sicknesses, yet additionally in the therapy and possible recuperation from such illnesses. The one-of-a-kind capability that different MMPs play in the body as well as the examples in which they are communicated give light on the possibility to novel harmless biomarkers and restorative targets. In preclinical examination, different MMPs and their inhibitors have been researched for the treatment of liver sicknesses by the debasement of col-I, the most predominant fibrotic extracellular matrix protein. Then again, the degrees of MMPs in the serum have been utilized as harmless biomarkers for organizing liver sicknesses like adrenoleukodystrophy (adrenoleukodystrophy-prompted fibrosis), hepatocellular carcinoma, and metastasis. These models feature the meaning of obtaining data about the possible utilizations of MMPs in the determination and treatment of liver problems.

Acknowledgement: *The authors are grateful to the Deanship of Scientific Research, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia for its support for this research work.*

REFERENCES

1. *Ando W, Yokomori H, Tsutsui N, Yamanouchi E, Suzuki Y., (2018).* Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. Clin. Mol. Hepatol. 24: 61-76 DOI: 10.3350/cmh.2017.0030
2. *Atkinson J, Colburn WA, DeGruttola VG., et al (2001).* Biomarkers and surrogate endpoints preferred definitions and conceptual framework Clinical Pharmacology and Therapeutics. 69(3): 89-95 DOI: 10.1067/mcp.2001.113989
3. *Attallah A, El-Far M, Abdel Malak CAA, Omran MM, Farid K., et al (2015).* Fibrocheck: A combination of direct and indirect markers for liver fibrosis staging in chronic hepatitis C patients. Ann Hepatol. 14: 225-233
4. *Bansal R, Nagórniewicz B, Prakash J (2016).* Clinical Advancements in the Targeted Therapies against Liver Fibrosis. Mediat. Inflamm. 1-16 DOI: 10.1155/2016/7629724
5. *Barr JM, Vazquez-Chantada C, Alonso C, Pérez-Cormenzana M, Mayo R., et al (2010).* Liquid chromatography – mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. Journal of Proteome Research. 9(9): 4501-4512 DOI: 10.1021/pr1002593
6. *Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG., et al (2010).* Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology. 51(1): 111-120 DOI: 1010.1002/hep.23271
7. *Binder MJ, McCoombe S, Williams ED, McCulloch D, Ward A (2017).* The extracellular matrix in cancer progression: Role of hyalectan proteoglycans and ADAMTS enzymes. Cancer Lett. 385: 55-64 DOI: 10.1016/j.canlet.2016.11.001
8. *Blachier M, Leleu H, Peck-Radosavljevic, Valla M, Roudot-Thoraval DF (2013).* The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol. 58: 593-608 DOI: 10.1016/j.jhep.2012.12.005
9. *Bodey B, Bodey B Jr, Siegel E, Kaiser HE (2000).* Immunocytochemical detection of MMP-3 and -10 expression in hepatocellular carcinomas. Anticancer Res. 20: 4585-4590

10. *Castera L (2012).* Noninvasive methods to assess liver disease in patients with hepatitis B or C". Gastroenterology. 142(6): 1293.e4-1302.e4 DOI: 10.1053/j.gastro.2012.02.017
11. *Castera L, Hezode CH, Roudot-Thoraval F, Roudot-Thoraval F, Lonjon I, Zafrani ES., et al (2004).* Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C indirect evidence of a role of hepatitis C virus genotype 3 in steatosis, Gut. 53(3): 420-424 DOI: 10.1136/gut.2002.009936
12. *Chuang HM, Chen YS, Harn HJ., (2019).* The Versatile Role of Matrix Metalloproteinase for the Diverse Results of Fibrosis Treatment. Molecules. 24: 4188 DOI: 10.3390/molecules24224188
13. *Consolo M, Amoroso A, Spandidos DA, Mazzarino MC (2009).* Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med. 24: 143-152 DOI: 10.3892/ijmm_00000217
14. *Cui N, Hu M, Khalil RA (2017).* Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog Mol Biol Transl Sci. 147: 1-73 DOI: 10.1016/bs.pmbts.2017.02.005
15. *Du C, Jiang M, Wei X, Qin J, Xu H., et al (2018).* Transplantation of human matrix metalloproteinase-1 gene-modified bone marrow-derived mesenchymal stem cell attenuates CCL4-induced liver fibrosis in rats. Int J Mol Med. 41: 3175-3184 DOI: 10.3892/ijmm.2018.3516
16. *El-Serag HB (2011).* The New England Journal of Medicine. 365(12): 1118-1127 DOI: 10.1056/NEJMra1001683
17. *Flannery CR (2006).* MMPs and ADAMTSs. Functional studies. Front Biosci. 11: 544569 DOI: 10.2741/1818
18. *Fonovic M, Turk B (2014).* Cysteine cathepsins and extracellular matrix degradation. Biochim, Biophys Acta.1840: 2560-2570 DOI: 10.1016/j.bbagen.2014.03.017
19. *Forde KA, Reddy KR (2009).* Hepatitis C Virus Infection and Immunomodulatory Therapies. Clin. Liver Dis. 13: 391-401 DOI: 10.1016/j.cld.2009.05.007
20. *Geervliet E, Bansal R (2020).* Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases. Cells. 9(5): 1212 DOI: 10.3390/cells9051212
21. *Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A., et al (2017).* Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 152: 1090-1099 DOI: 10.1053/j.gastro.2017.01.003
22. *Gross J, Lapière CM (1962).* Collagenolytic Activity in Amphibian Tissues: A Tissue Culture Assay. Proc Natl Acad Sci. USA. 48: 1014-1022 DOI: 10.1073/pnas.48.6.1014
23. *Huang CC, Chuang JH, Chou MH, Wu CL, Chen CM., et al (2005).* Matrilysin (MMP-7) is a major matrix metalloproteinase upregulated in biliary atresia-associated liver fibrosis. Mod Pathol. 18: 941-950 DOI: 10.1038/modpathol.3800374
24. *Iimuro Y, Nishio T, Morimoto T, Nitta T, Stefanovic B, Choi SK, Brenner DA, Yamaoka Y (2003).* Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterol. 124: 445-458 DOI: 10.1053/gast.2003.50063
25. *Iredale J (1997).* Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem. Cell Biol. 29: 43-54 DOI: 10.1016/s1357-2725(96)00118-5
26. *Lawson A, Hagan S, Rye K., et al (2007).* The natural history of hepatitis C with severe hepatic fibrosis, Journal of Hepatology. 47(1): 37-45 DOI: 10.1016/j.jhep.2007.02.010
27. *Lichtinghagen R, Bahr MJ, Wehmeier M, Michels D, Haberkorn CI., et al (2003).* Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci. 105: 373-382 DOI: 10.1042/CS20030098
28. *Löffek S, Schilling O, Franzke CW (2011).* Series 'matrix metalloproteinases in lung health and disease edited by J. Müller-Quernheim and O. Eickelberg number 1 in this series: Biological role of matrix metalloproteinases: A critical balance. Eu:r Respir J. 38: 191-208 DOI: 10.1183/09031936.00146510

29. *Lu P, Takai K,Weaver VM,Werb Z (2011).* Extracellular Matrix Degradation and Remodeling in Development and Disease. Cold Spring Harb Perspect Biol. 3: a005058 DOI: 10.1101/cshperspect.a005058

30. *Madzharova, Kastl E, Sabino P, Keller FMR, UAD (2019).* Post-Translational Modification-Dependent Activity of Matrix Metalloproteinases. Int J Mol Sci. 20: 3077 DOI: 10.3390/ijms20123077

31. *Mari CR, Louis B, Rostagno K, Saint-Paul P, Giudicelli MC., et al (2002).* Rat liver injury following normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J. 16: 93-95 DOI: 10.1096/fj.01-0279fje

32. *Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Yao Chang Liu, McCullough AJ (1999).* Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology. 116(6): 1413-1419 DOI: 10.1016/s0016-5085(99)70506-8

33. *Mildvan DA, Landay, V de Gruttola, Machado SG, Kagan J (1997).* An approach to the validation of markers for use in AIDS clinical trials, Clinical Infectious Diseases. 24(5): 764-774 DOI: 10.1093/clinids/24.5.764

34. *Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H (2002).* Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol. 14: 138-145 DOI: 10.1046/j.1440-1746.1999.01821.x

35. *Ngo Y, Munteanu M, Messous D., et al (2006).* A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C, Clinical Chemistry. 52(10): 1887-1896 DOI: 10.1373/clinchem.2006.070961

36. *Okamoto K, Mandai M, Mimura K, Murawaki Y, Yuasa I (2005).* The association of MMP-1, -3 and -9 genotypes with the prognosis of HCV-related hepatocellular carcinoma patients. Res Commun Mol Pathol Pharmacol. 117-118, 77-89

37. *Onozuka I, Kakinuma S, Kamiya A, Miyoshi M, Sakamoto N., et al (2011).* Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. Biochem Biophys Res Commun. 406: 134-140 DOI: 10.1016/j.bbrc.2011.02.012

38. *Parkes J, Guha IN, Roderick P., et al (2011).* Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C, Journal of Viral Hepatitis. 18(1): 23-31 DOI: 10.1111/j.1365-2893.2009.01263.x

39. *Poynard T, Bedossa P, Opolon P (1997).* Natural history of liver fibrosis progression in patients with chronic hepatitis C. The Lancet. 349(9055): 825-832 DOI: 10.1016/s0140-6736(96)07642-8

40. *Prystupa A, Boguszewska-Czubara A, Bojarska-Junak A, Toru n-Jurkowska A, Roli ´nski J, Załuska W (2015).* Activity of MMP-2, MMP-8 and MMP-9 in serum as a marker of progression of alcoholic liver disease in people from Lublin Region, eastern Poland. Ann Agric Environ Med. 22: 325-328 DOI: 10.5604/12321966.1152088

41. *Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C., et al (2009).* The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 50(6): 1827-1838 https://doi.org/10.1002/hep.23229

42. *Radbill BD, Gupta R, Ramirez MCM, DiFeo A, Martignetti JA., et al (2011).* Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin-Induced Liver Fibrosis by Upregulating Collagen I Expression. Dig. Dis. Sci. 56: 406-416 DOI: 10.1007/s10620-010-1296-0

43. *Rincon D, Lo Iacono O, Ripoll C., et al (2007).* Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis, Alimentary Pharmacology and Therapeutics. 25(7): 841-848 DOI: 10.1111/j.1365-2036.2007.03258.x

44. *Ripoll C, Lastra P, Rincon D, Catalina V, Ba Raares (2012).* Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis, Scandinavian Journal of Gastroenterology. 47(2): 204-211 DOI: 10.3109/00365521.2011.645500

45. *Roeb E (2018).* Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol. 68-69, 463-473 DOI: 10.1016/j.matbio.2017.12.012

46. *Sooderberg C, Stal P, Askling J, Glaumann H, Lindberg G., et al (2010).* Decreased sur-

vival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 51(2): 595-602 DOI: 10.1002/hep.23314

47. *Sternlicht MD, Werb Z (2001).* How Matrix Metalloproteinases Regulate Cell Behavior. Annu Rev Cell Dev Biol. 17: 463-516 DOI: 10.1146/annurev.cellbio.17.1.463
48. *Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A (1997.)* Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology. 26: 1521-1599 DOI: 10.1002/hep.510260620
49. *Teli MR, James OFW, Burt AD, Bennett MK, Day CP (1995).* The natural history of nonalcoholic fatty liver: a follow up study, Hepatology. 22(6): 1714-1719
50. *Vergniol J, Foucher J, Terrebonne E., et al (2011).* Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C, Gastroenterology. 140(7): 1970.e3-1979.e3 DOI: 10.1053/j.gastro.2011.02.058
51. *Yano M, Kumada H, Kage M., et al (1996).* The long-term pathological evolution of chronic hepatitis C. Hepatology. 23(6): 34-1340 DOI: 10.1002/hep.510230607
52. *Younossi ZM, Baranova A, Ziegler K., et al (2005).* A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease, Hepatology. 42(3): 665-674 DOI: 10.1002/hep.20838
53. *Zhou Z, Ma X, Wang F-M, Sun L, Zhang G (2018).* A Matrix Metalloproteinase-1 Polymorphism, MMP1–1607 (1G>2G), Is Associated with Increased Cancer Risk: A Meta-Analysis Including 21,327 Patients. Dis Markers. 1-12 DOI: 10.1155/2018/7565834

THE NEW ARMENIAN MEDICAL JOURNAL

Volume18 (2024). Issue 3

The Journal is founded by
Yerevan State Medical
University after M. Heratsi.

Rector of YSMU

Armen A. Muradyan

Address for correspondence:

Yerevan State Medical University
2 Koryun Street, Yerevan 0025,
Republic of Armenia

Phones:

(+37410) 582532 YSMU
(+37493 588697 Editor-in-Chief
Fax: (+37410) 582532
E-mail:namj.ysmu@gmail.com, ysmiu@mail.ru
URL:http//www.ysmu.am

Our journal is registered in the databases of Scopus, EBSCO and Thomson Reuters (in the registration process)

Scopus *EBSCO*
Reuters

Copy editor: Tatevik R. Movsisyan

Printed in "LAS Print" LLC
Director: Suren A. Simonyan
Armenia, 0023,Yerevan,
Acharyan St. 44 Bulding,
Phone: (+374 10) 62 76 12,
E-mail: las.print@yahoo.com

THE NEW ARMENIAN MEDICAL JOURNAL
Volume18 (2024). Issue 3

CONTENTS